Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7108)
All Articles published online
|
Publishing Process of This Article
|
May 7, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pallagi-Kunstár &, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035 [PMID: 24833846 DOI: 10.3748/wjg.v20.i17.5031] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i17/5031.htm |
| Number | Citing Articles |
| 1 |
Yun Qiu, Ren Mao, Bai-li Chen, Sheng-hong Zhang, Jing Guo, Yao He, Zhi-rong Zeng, Shomron Ben-Horin, Min-hu Chen. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clinical Gastroenterology and Hepatology 2017; 15(9): 1359 doi: 10.1016/j.cgh.2017.02.005
|
| 2 |
Stanisław Pieczarkowski, Kinga Kowalska-Duplaga, Andrzej Wędrychowicz, Krzysztof Fyderek, Przemko Kwinta, Agnieszka Radom, Andrzej Zając, Przemysław Tomasik. Calprotectin (S100 A8/A9) and TNF-alpha in differential diagnosis of chronic abdominal pain in children. Diagnostyka Laboratoryjna 2017; 53(1): 5 doi: 10.5604/01.3001.0013.7957
|
| 3 |
T. Yu. Nuriahmetova, I. Kh. Valeeva, Y. O. Shevnina, A. V. Petrov, N. A. Cheremina, E. V. Sukhorukova, A. G. Vasiliev, D. I. Abdulganieva. Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases: focus on immunogenicity. Modern Rheumatology Journal 2023; 17(4): 35 doi: 10.14412/1996-7012-2023-4-35-41
|
| 4 |
Tsunekazu Mizushima, Tadafumi Fukata, Hiroshi Takeyama, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori. The features of adipose-derived stem cells in patients with inflammatory bowel diseases. Surgery Today 2018; 48(3): 352 doi: 10.1007/s00595-017-1591-x
|
| 5 |
M Rinaudo-Gaujous, X Roblin, H Marotte, S Paul. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Annals of the Rheumatic Diseases 2015; 74(8): e40 doi: 10.1136/annrheumdis-2015-207503
|
| 6 |
Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara, Masataka Kuwana. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. PLOS ONE 2021; 16(10): e0258601 doi: 10.1371/journal.pone.0258601
|
| 7 |
Guanglin Cui, Jon Florholmen, Rasmus Goll. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.881112
|
| 8 |
Chen Li, Xia Wu, Yihan Cao, Yueping Zeng, Weihong Zhang, Shuo Zhang, Yuehua Liu, Hongzhong Jin, Wen Zhang, Li Li. Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome. Clinical Rheumatology 2019; 38(1): 53 doi: 10.1007/s10067-018-4083-5
|
| 9 |
Filipa Silva-Ferreira, Joana Afonso, Pedro Pinto-Lopes, Fernando Magro. A Systematic Review on Infliximab and Adalimumab Drug Monitoring. Inflammatory Bowel Diseases 2016; 22(9): 2289 doi: 10.1097/MIB.0000000000000855
|
| 10 |
B Gorovits, D J Baltrukonis, I Bhattacharya, M A Birchler, D Finco, D Sikkema, M S Vincent, S Lula, L Marshall, T P Hickling. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clinical and Experimental Immunology 2018; 192(3): 348 doi: 10.1111/cei.13112
|
| 11 |
Mingke Jiao, Hong Yin, Jie Hu, Wenjuan Xu, Xiao Zhang, Peng Zhang. Effects of Low-Frequency Pulsed Electromagnetic Fields on High-Altitude Stress Ulcer Healing in Rats. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/6354054
|
| 12 |
Franco Scaldaferri, Daria D‘Ambrosio, Grainne Holleran, Andrea Poscia, Valentina Petito, Loris Lopetuso, Cristina Graziani, Lucrezia Laterza, Maria Teresa Pistone, Silvia Pecere, Diego Currò, Eleonora Gaetani, Alessandro Armuzzi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini, Fabio Cominelli. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLOS ONE 2017; 12(10): e0186575 doi: 10.1371/journal.pone.0186575
|
| 13 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, J. de-Paula, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.L. Rocha, F. Steinwurz, G. Veitia, C. Zaltman. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017; 82(1): 46 doi: 10.1016/j.rgmx.2016.07.003
|
| 14 |
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Elena Penza, Ottavia Magnani, Francesco Puppo. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. Expert Opinion on Drug Safety 2016; 15(1): 43 doi: 10.1517/14740338.2016.1112375
|
| 15 |
Scott D. Lee, Raina Shivashankar, Daniel Quirk, Haiying Zhang, Jean-Baptiste Telliez, John Andrews, Amy Marren, Arnab Mukherjee, Edward V. Loftus. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Journal of Clinical Gastroenterology 2021; 55(3): 195 doi: 10.1097/MCG.0000000000001396
|
| 16 |
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. eBioMedicine 2021; 66: 103329 doi: 10.1016/j.ebiom.2021.103329
|
| 17 |
Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021; 13(11): 1786 doi: 10.3390/pharmaceutics13111786
|
| 18 |
Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe, Mi-Jin Kim. Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease. Biomedicines 2022; 10(10): 2372 doi: 10.3390/biomedicines10102372
|
| 19 |
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, M.A. Martínez-Vázquez. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. Revista de Gastroenterología de México (English Edition) 2021; 86(1): 70 doi: 10.1016/j.rgmxen.2020.10.007
|
| 20 |
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, M.A. Martínez-Vázquez. Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista de Gastroenterología de México 2021; 86(1): 70 doi: 10.1016/j.rgmx.2020.10.001
|
| 21 |
Séverine Vermeire, Ann Gils, Paola Accossato, Sadiq Lula, Amy Marren. Immunogenicity of biologics in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2018; 11: 1756283X1775035 doi: 10.1177/1756283X17750355
|
| 22 |
Syed B Ali, Amelia Cecchin, Cristina Lucchesi, Trishni Putty, Suzanne Edwards, Tina Petrou, Penelope Coates, Antonio Ferrante, Phillippa A Pucar, Jovanka King, Tatjana Banovic. Can C-reactive protein be used as a surrogate marker of IL-6 in a broad array of clinical entities?. Biomarkers in Medicine 2023; 17(24): 1001 doi: 10.2217/bmm-2023-0708
|
| 23 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, J. de-Paula, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.L. Rocha, F. Steinwurz, G. Veitia, C. Zaltman. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México (English Edition) 2017; 82(1): 46 doi: 10.1016/j.rgmxen.2016.07.003
|
| 24 |
Zhe Wang, Xue Ya Liang, Xin Chang, Yao Yan Nie, Chen Guo, Jin Hong Jiang, Min Chang. MMI-0100 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice through Targeting MK2 Pathway. Molecules 2019; 24(15): 2832 doi: 10.3390/molecules24152832
|
| 25 |
Joel Tan Joel Tan, Teresa Neeman, Kavitha Subramaniam Kavitha Subramaniam. The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease. Gastroenterology & Hepatology: Open Access 2022; 13(2): 53 doi: 10.15406/ghoa.2022.13.00494
|
| 26 |
Kata Judit Szántó, Tamara Madácsy, Diána Kata, Tamás Ferenci, Mariann Rutka, Anita Bálint, Renáta Bor, Anna Fábián, Ágnes Milassin, Boldizsár Jójárt, Zoltán Szepes, Ferenc Nagy, Tamás Molnár, Imre Földesi, József Maléth, Klaudia Farkas. Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists. Expert Opinion on Biological Therapy 2021; 21(4): 539 doi: 10.1080/14712598.2021.1890712
|
| 27 |
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Health Technology Assessment 2016; 20(83): 1 doi: 10.3310/hta20830
|
| 28 |
Konstantinos Papamichael, Adam S Cheifetz. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterology 2016; 7(4): 289 doi: 10.1136/flgastro-2016-100685
|
| 29 |
Vibeke Strand, Alejandro Balsa, Jamal Al-Saleh, Leonor Barile-Fabris, Takahiko Horiuchi, Tsutomu Takeuchi, Sadiq Lula, Charles Hawes, Blerina Kola, Lisa Marshall. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017; 31(4): 299 doi: 10.1007/s40259-017-0231-8
|
| 30 |
Omoniyi J. Adedokun, William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Zhenhua Xu, Colleen W. Marano, Jewel Johanns, Honghui Zhou, Hugh M. Davis, Freddy Cornillie, Walter Reinisch. Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis. Gastroenterology 2014; 147(6): 1296 doi: 10.1053/j.gastro.2014.08.035
|